Latterell Venture Partners
Latterell Venture Partners is a San Ramon, California-based venture capital firm founded in 2001 that invests exclusively in early-stage healthcare companies across biotechnology, pharmaceuticals, medical devices, healthcare IT, and diagnostics. The firm provides capital, operational support, and board oversight to startup founders seeking to develop new disease treatments.
- Company typePrivate
- Founded2001
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Latterell Venture Partners firmographics
Firmographics- Name
- Latterell Venture Partners
- Legal name
- Latterell Venture Partners
- Website
- https://lvpcapital.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Latterell Venture Partners is a San Ramon, California-based venture capital firm founded in 2001 that invests exclusively in early-stage healthcare companies across biotechnology, pharmaceuticals, medical devices, healthcare IT, and diagnostics. The firm provides capital, operational support, and board oversight to startup founders seeking to develop new disease treatments.
- Ownership category
- akta.pro rank
Latterell Venture Partners industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (52394), Other Financial Vehicles (52599)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where Latterell Venture Partners is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Latterell Venture Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Investment Returns from Portfolio Companies: LVP generates returns through successful exits of portfolio companies via IPOs and mergers and acquisitions. The firm invests in early stage healthcare companies and supports them through subsequent private equity financings, with an expectation to invest $10-$20 million in each portfolio company over time. Successful exits mentioned include Proteolix (acquired by Onyx for up to $851M), Transcend (acquired by Alcon/Novartis for up to $740M), Naurex (acquired for $560M plus milestones), Pulmonx (IPO in September 2020), Viracta (IPO in February 2021), and numerous other acquisitions and IPOs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Latterell Venture Partners product offering
Product offeringCore offering
Latterell Venture Partners is an early-stage venture capital firm that invests equity capital in healthcare startups developing biopharmaceuticals, medical devices, healthcare IT, diagnostics, biomaterials, and research instruments. In addition to capital, the firm provides operational, technical, clinical, and strategic support to entrepreneurs, including interim management, board participation, and assistance with follow-on financings aimed at successful exits via IPO or acquisition.
Product overview
Latterell Venture Partners is an early-stage healthcare venture capital firm that provides investment capital, entrepreneurial support, operational expertise, and strategic guidance to startups in biotechnology, pharmaceutical development, medical devices, research instruments, biomaterials, healthcare information technology, and diagnostics. The firm does not offer a standalone product but rather delivers value-added investment services, including business strategy refinement, management team recruitment, board participation, and follow-on financing support to help portfolio companies achieve successful exits via IPO or merger.
Differentiator
Problem solved
Functional benefit
Products and services
- Early-Stage Healthcare Venture Capital Investment
- Value-Added Operational and Strategic Support for Portfolio Companies
Quantifiable outcome
- Multiple successful exits including Proteolix ($851M to Onyx), Transcend ($740M to Alcon/Novartis), Naurex ($560M+), Pulmonx (IPO 2020), Viracta (IPO 2021)
Companies that use Latterell Venture Partners
Customer profileNamed customers17 records
Segments1 record
Ideal customer profiles1 record
Latterell Venture Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Latterell Venture Partners partnerships and signals
Strategic signalScale indicators6 records
Recent moves7 records
Expansion highlights4 records
Latterell Venture Partners competitors and assessment
Company assessmentDirect peers
- Versant Ventures: Healthcare-focused venture firm investing in early-stage biopharma, medtech, and healthcare services. Directly comparable given its early-stage focus, Bay Area presence, and operator-heavy team model.
- ARCH Venture Partners: Early-stage venture firm investing in science-driven companies across biotech, medtech, and cleantech. Directly comparable for early-stage life sciences investing with university spin-out focus.
- Longitude Capital: Healthcare-dedicated growth and venture firm investing across biopharma, medtech, and healthcare services. Directly comparable as a sector-focused firm with similar check sizes and stage focus.
- Domain Associates: Healthcare and life sciences venture firm investing across therapeutics, medical devices, and diagnostics. Directly comparable as a sector-specialist VC with a similar exit-driven model and Bay Area roots.
- Alta Partners: Healthcare-focused venture firm with a long track record in biopharma and medtech. Comparable as a similar-sized, similarly specialized VC with overlapping therapeutic and device focus.
- OrbiMed Advisors: Dedicated healthcare investment firm covering biopharma, medtech, and diagnostics across all stages. Directly comparable as a healthcare-only specialist investor with deep scientific bench and multi-stage investing approach.
- Venrock Associates: Multi-stage venture firm with a longstanding healthcare and life sciences practice. Directly comparable to LVP because Pat Latterell himself was a 14-year General Partner at Venrock before founding LVP, making it the most direct lineage peer.
- 5AM Ventures: Early-stage life sciences venture firm focused on founder-led biotech startups. Comparable as a similarly-sized specialist in early-stage therapeutics and platform companies with operating-partner model.
- Frazier Healthcare Partners: Healthcare-dedicated venture and growth firm investing across biopharma and medtech from early to later stages. Directly comparable as a long-standing sector-focused VC with deep operating expertise.
Broad incumbents
- New Enterprise Associates (NEA): Large multi-stage venture firm with one of the largest dedicated healthcare practices. Broadly comparable given overlapping healthcare investments and life sciences expertise, but operates at much greater scale across multiple sectors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Latterell Venture Partners social profiles
Digital presenceLatterell Venture Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Latterell Venture Partners leadership team
Management profileNumber of profiles
Profiles6 records
Latterell Venture Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Latterell Venture Partners M&A and investment
M&A and investmentM&A
Investments58 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Latterell Venture Partners
What does Latterell Venture Partners do?
Latterell Venture Partners is an early-stage venture capital firm that invests equity capital in healthcare startups developing biopharmaceuticals, medical devices, healthcare IT, diagnostics, biomaterials, and research instruments. In addition to capital, the firm provides operational, technical, clinical, and strategic support to entrepreneurs, including interim management, board participation, and assistance with follow-on financings aimed at successful exits via IPO or acquisition.
Is Latterell Venture Partners a public or private company?
Latterell Venture Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Latterell Venture Partners founded?
Latterell Venture Partners was founded in 2001. It employs 1 to 10 people.
Where is Latterell Venture Partners based?
Latterell Venture Partners is headquartered in San Francisco, United States, in the North America region.
How does Latterell Venture Partners make money?
One revenue line is on record: investment Returns from Portfolio Companies.
Who are Latterell Venture Partners's main competitors?
Direct peers on record are Versant Ventures, ARCH Venture Partners, Longitude Capital, Domain Associates, Alta Partners, OrbiMed Advisors, Venrock Associates, 5AM Ventures and Frazier Healthcare Partners. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does Latterell Venture Partners have an API?
No public API is recorded for Latterell Venture Partners.
What industry is Latterell Venture Partners in?
Latterell Venture Partners's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 52394 and its SIC code is 6282.